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bstract
ntroduction:  In Western medicine, non-alcoholic fatty liver disease (NAFLD) is diagnosed by imaging, histology and biochemical parameters
raditional Chinese Medicine (TCM) uses unique diagnostic techniques to classify NAFLD into subtypes based on different TCM symptoms
syndrome classification). Sterol regulatory element-binding protein (SREBP), also known as SREBP cleavage-activating protein or SCAP is
ncoded by the SCAP gene SCAP genes have important functions in defining genetic susceptibility to NAFLD. This study investigated whether
he polymorphisms of SREBF-1, SREBF-2, and SCAP genes were associated with the TCM syndromes of NAFLD.
aterials  and  methods:  Fourteen tag single nucleotide polymorphisms (SNPs) of SREBF-1, SREBF-2, and SCAP were chosen for our study We
enotyped and analyzed 100 healthy control subjects and 211 NAFLD subjects who were classified by TCM into two groups, namely, deficiency
yndrome group and excess syndrome group.
esults:  The results showed that rs12636851 SNP of SCAP exhibited a significant genotype and allelic variation between the deficiency syndrome
nd healthy control subjects, as well as between the deficiency and excess syndrome subjects In the deficiency syndrome group, the subjects who
ad the CC or TC genotype of SCAP rs12636851 had a threefold elevated risk for NAFLD compared with the TT genotype (adjusted OR, 3107;
5% CI, 1023–9433, P  = 0.045; adjusted OR, 2970; 95% CI, 1121–7864, P  = 0.028).
iscussion:  We speculate that the SCAP rs12636851 SNP in the deficiency syndrome subjects affects the cholesterol-sensing function of SCAP,
ncreasing cholesterol and fatty acid synthesis in liver Therefore, this SNP may help in the understanding of the genetic basis of NAFLD patients
ith deficiency syndrome and in the development of personalized medical care.
 2013 Elsevier GmbH. All rights reserved.
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Non-alcoholic fatty liver disease (NAFLD) is recognized as
ne of the most common causes of chronic liver disease world-
ide [1]. The prevalence of NAFLD is about 15–30% in the
eneral population of various countries [2]; approximately 20%
n China [3,4]. NAFLD is diagnosed by imaging or histology as
ell as biochemical parameters in western medicine. However,
n clinical practice patients with NAFLD present with differ-
nt clinical symptoms. Traditional Chinese Medicine (TCM)
ses a unique diagnostic technique to classify NAFLD into
ubtypes based on these different TCM symptoms (called as
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CM syndrome classification). This method of classifications
imits the clinical heterogeneity of NAFLD and provides a basis
or developing a classified treatment protocol.
The pathogenesis of NAFLD is complex and multifactorial,
s environmental and genetic factors interact with each other
5,6]. Environmental factors such as excessive calorie intake
nd a lack of daily physical activity are undoubtedly fuelling
he epidemic of NAFLD [6,7]. However, environmental factors
re not solely responsible for the NAFLD problem. In clini-
al practice, there are individual variations in susceptibility to
he development of NAFLD that is, some individuals develop
AFLD, whereas others remain unaffected even when shar-
ng a similar moderate lifestyle. These observations suggest
hat innate, non-environmental factors make some individuals
ore susceptible to NAFLD. In the recent years, several genes
ave been suggested potentially associated with NAFLD-related
raits in the general population [8–10]; however, the contribution
f genetic polymorphisms to the disease susceptibility is still
nconclusive. As cholesterol and fatty acid metabolism plays
n important role in NAFLD pathogenesis [11], genetic varia-
ions in candidate genes related to dyslipidemia susceptibility
ay be associated with NAFLD. Sterol regulatory element-
inding protein (SREBP) is one of the major regulators of lipid
etabolism, especially in cholesterol and fatty acid synthesis
12]. SREBPs are produced from separated genes named sterol
egulatory element-binding factors-1 (SREBF-1) and SREBF-2
13]. The SREBP cleavage activating protein (SCAP) is involved
n maturation of both SREBPs [14] and transports SREBPs from
he endoplasmic reticulum to the Golgi complex. The SREBPs
re subsequently activated and translocated into the nucleus.
he SREBPs bind to SREBP response element to stimulate the
xpression of target genes, encoding enzymes for synthesis and
ptake of cholesterol and triglyceride [15,16].
Therefore, SREBF-1, SREBF-2, and SCAP genes have
mportant functions in defining genetic susceptibility to NAFLD.
oreover, the different genotypes of these genes can possi-
ly distinguish the NAFLD subtypes. In the current study, we
nvestigated whether the polymorphism of SREBF-1, SREBF-
, and SCAP genes are associated with the TCM syndromes of
AFLD.
aterials  and  methods
ubjects
This study was conducted at Longhua Hospital, which is
ffiliated to the Shanghai University of TCM and Fenglin Com-
unity Hospital in the Xuhui District of Shanghai, from August
009 to May 2010. A total of 311 unrelated individuals were
nrolled in this study, of the total number subjects, 211 indi-
iduals were diagnosed with NAFLD, and the remaining 100
ndividuals were selected as healthy control subjects with no
istory of fatty liver.linical  and  laboratory  evaluation
See Supplementary materials and methods.
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iagnostic  criteria
NAFLD was diagnosed according to the guidelines for the
iagnosis and treatment of NAFLDs issued by the Fatty Liver
nd Alcoholic Liver Disease Study Group of the Chinese Liver
isease Association (2008 and 2010) [17] (see Supplementary
aterials and methods).
In order to determine TCM syndromes, NAFLD sub-
ects completed questionnaires which included 30 symptoms
Table 1), which were clustered into two specific groups using a
-means cluster analysis. Coincidentally, the two groups were
imilar to the deficiency syndrome and excess syndrome of the
CM theory based on “Textbooks for general tertiary education
f Chinese medicine: diagnosis of Chinese medicine”, which
as edited and authorized by Ministry of Health of China [18].
ymptoms less correlated to the TCM syndrome classification of
AFLD or did not correspond to the TCM theory were excluded
Supplementary Fig. S1). Finally, a 12-item scoring table for the
CM diagnosis of NAFLD was finalized; each diagnostic cat-
gory comprised eight symptoms including 2 main symptoms
nd 6 minor symptoms (Supplementary Table S2). The two main
ymptoms each corresponded to two points and the other symp-
oms corresponded to one point. As a result, the category that
eceived a score of five points or higher was considered to defi-
iency or excess syndrome. If two categories received a score
f five points or higher, the patient was considered to have a
eficiency and excess coexisting syndrome. If two categories
eceived a score less than five points, the patient was considered
o have no syndrome. The small population of the deficiency and
xcess coexisting syndrome and no syndrome (6.2% and 5.2%)
n present study decreased the power to detect differences, thus
ere excluded in the analysis. Therefore, a total of 287 sub-
ects with the deficiency or excess syndrome were enrolled in
he following analysis (Fig. 1).
ag  SNPs  selection
A tag SNP is a representative SNP in a region of the genome
ith high linkage disequilibrium, which could predict the rest
f the SNPs with a small error. Thus, when performing a disease
ssociation study, the geneticist would experimentally test for
ssociation by considering only the tag SNPs, thereby consid-
rably saving resources. We selected tag SNPs (tSNPs) using
enotype data obtained from the International HapMap Project
http://hapmap.ncbi.nlm.nih.gov) (release # 27/PhaseII+III Feb
9). This study aims to define a set of tSNPs that have an esti-
ated r2 > 0.8 compared with the untyped SNPs [19]. Using the
aploview 4.2 program (http://www.broad.mit.edu/haploview/
aploview-downloads), we selected the tSNPs having a minor
llele frequency of >0.05 in Chinese Han Beijing (CHB). There-
ore, a total of 14 SNPs were chosen for this study.NP  genotyping  assays
SNPs were typed using iPLEX chemistry on a matrix-assisted
aser desorption/ionization time-of-flight mass spectrometer
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Table 1
Clinical and biological characteristics of subjects in four groups.
Characteristics Total NAFLD
NAFLD (n = 187) Healthy control (n = 100) Xu pattern (n = 91) Shi pattern (n = 96)
Female (%) 62.6 57.0 63.7 61.5
Age (years) 69.96 ± 8.70 66.65 ± 5.30* 70.89 ± 8.95 69.08 ± 8.42
Smokers (%) 13.9 10.0 14.3 13.5
BMI (kg/m2) 26.07 ± 2.89 22.82 ± 1.54** 25.92 ± 2.56 26.21 ± 2.82
FPG (mmol/L) 7.51 ± 2.29 5.13 ± 0.81** 7.46 ± 2.28 7.57 ± 2.3
SBP (mmHg) 138.01 ± 15.46 128.74 ± 6.54** 137.85 ± 15.02 138.17 ± 15.93
DBP (mmHg) 79.38 ± 9.74 75.24 ± 5.89** 78.88 ± 9.46 79.85 ± 10.02
TG (mmol/L) 1.73 ± 1.10 1.14 ± 0.33** 1.73 ± 0.98 1.67 ± 1.04
TC (mmol/L) 5.32 ± 0.96 4.73 ± 0.73** 5.43 ± 0.95 5.21 ± 0.95
HDL-c (mmol/L) 1.28 ± 0.34 1.45 ± 0.37** 1.32 ± 0.42 1.24 ± 0.24
LDL-c (mmol/L) 3.19 ± 0.97 2.93 ± 0.74* 3.33 ± 0.91 3.04 ± 1.00***
VLDL (mmol/L) 2.54 ± 0.61 2.48 ± 0.54 2. 61 ± 0.60 2.48 ± 0.60
ALT (U/L) 26.79 ± 13.6 25.33 ± 13.2 27.02 ± 13.81 26.58 ± 13.41
AST (U/L) 20.86 ± 7.54 19.30 ± 5.44 20.53 ± 7.38 21.17 ± 7.71
BMI, body mass index; FPG, fasting plasma glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, triglyceride; TC, total cholesterol; HDL-c,
high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; VLDL-c, very-low-density lipoprotein cholesterol; ALT, alanine transaminase;
AST, aspartate transaminase.
* P < 0.05 vs. the healthy control group.
** P < 0.01 vs. the healthy control group.
*** P < 0.05 vs. the Shi pattern group.
Ass essed  for eli gibilit y
(n=311 )
Exclud ed  (n=24),  since   the  small  
population   dec rease d  the po wer  to 
detect  diff erence s.
No synd rome (n=11 );  deficiency and  
exces s coexisting  synd rome (n=13 ).
Enroll ed in  the  foll owing  
analysis (n=287 )
Healthy  contr ol gou rp (n=100 )
NAFLD grou p(n=18 7): Defi ciency  synd rome   
(n=91), Excess syndrome (n=96)
14 SNPs of SREBF-1,  SREBF-2
and  SCAP
Defi ciency  
synd rome
(n=91)
Healthy  
con trol
(n=100 )
Excess  
synd rome 
(n=96 )
Rs1263685 1 SNP  of 
SCAP was  diff erent
betwee n the two grou ps
Fig. 1. Flow diagram.
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nd Methods).
tatistical  analysis
The Hardy–Weinberg equilibrium was calculated using
oodness-of-fit χ2-tests to compare the observed genotype
requencies with the expected genotype frequencies in the
ealthy control group. Continuous variables were expressed as
ean ±  standard deviation and the differences between groups
ere compared by Student’s t-test or Kruskal–Wallis test. Cat-
gorical variables were expressed as the number of cases and
ercentage. The results were then compared using the χ2-test
r Fisher’s test. Odds ratios (ORs) and 95% confidence interval
CI) were calculated separately using binary logistic regression
nalysis adjusted for gender, age, smoking status, and BMI. We
erformed binary logistic regression analysis by assuming an
dditive and dominant model. An additive model referred to
 variable coded 0, 1, 2 for the three genotypes AA (major
omozygous), Aa (heterozygous), and aa (minor homozygous).
he codes were then entered into binary logistic regression
nalysis as integers in the model. A dominant model coded
he genotypes as 0 = AA (major homozygous) and 1 = Aa + aa
heterozygous combined with minor homozygous). Two-sided
 values of <0.05 were considered statistically significant. All of
hese statistical analyses were conducted in SPSS version 17.0
SPSS Software, Chicago, IL, USA).
esultsThe clinical and laboratory characteristics of the four groups
ere listed in Table 1. Compared with the healthy controls, the
AFLD subjects including the excess and deficiency syndrome
S. Sun et al. / European Journal of Integrative Medicine 5 (2013) 386–392 389
Table 2
Conditional logistic regression analysis assuming additive and dominant model between Xu pattern group and healthy control group.
SNP Genotype call number Major allele/minor allele Adjusted OR, 95% CI, P 2, P Phwecontrol
(Dominant model) (Additive model)
SREBF1
4925115 277 A/G 1.473, 0.659–3.291, 0.346 1.492, 0.766–2.906, 0.240 1.170, 0.555 0.705
8066560 286 A/G 1.575, 0.717–3.459, 0.258 1.573, 0.814–3.041, 0.178 2.725, 0.250 0.804
2282180 286 G/A 0.641, 0.285–1.442, 0.282 0.645, 0.314–1.326, 0.233 1.356, 0.509 0.871
9902941 285 C/T 1.450, 0.661–3.178, 0.354 1.488, 0.773–2.864, 0.234 3.374, 0.184 0.911
SREBF2
2228314 286 G/C 0.527, 0.233–1.191, 0.124 0.608, 0.306–1.211, 0.157 3.638, 0.158 0.711
5996080 286 T/C 0.535, 0.194–1.470, 0.225 0.626, 0.252–1.553, 0.312 2.311, 0.272 0.708
2267438 276 T/C 1.442, 0.597–3.484, 0.416 1.357, 0.742–2.482, 0.321 1.112, 0.580 0.022
9607852 287 G/A 3.141, 0.462–21.373, 0.242 3.141, 0.462–21.373, 0.242 1.370, 0.314 0.846
4822062 287 G/A 0.887, 0.281–2.200, 0.838 0.873, 0.284–2.686, 0.812 1.228, 0.674 0.858
17379759 286 A/G 0.322, 0.051–2.014, 0.226 0.322, 0.051–2.014, 0.226 0.720, 0.443 0.894
SCAP
12636851 286 C/T 3.017, 1.208–7.532, 0.018 1.767, 1.022–3.054, 0.041 11.090, 0.004 0.365
2306628 287 C/T 1.998, 0.647–6.170, 0.229 1.998, 0.647–6.170, 0.229 1.257, 0.283 0.883
4858889 270 A/G 1.128, 0.459–2.773, 0.793 1.086, 0.498–2.367, 0.836 1.199, 0.532 1.000
17079634 287 T/C 1.306, 0.538–3.170, 0.555 1.201, 0.550–2.621, 0.646 0.316, 0.868 0.848
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ddjusted OR = adjusted for age, gender, smoking status, BMI.
he mean genotype call rate was 98.8%.
roups exhibited higher values for body mass index (BMI), fas-
ing plasma glucose (FPG), serum lipid, and blood pressure.
n the NAFLD group, no significant differences were found
etween the excess and deficiency syndrome subjects for the
linical and laboratory characteristics, except for the slightly
igher low-density lipoprotein cholesterol (LDL-c) in the defi-
iency syndrome group (P  = 0.039).
All the SNPs passed the Hardy–Weinberg equilibrium test
P > 0.05, Table 2) in the healthy control group. The associations
etween the phenotypes and 14 SNPs were shown in Table 2
nd Supplementary Tables 3 and 4. Only the SCAP rs12636851
NP was found to be significantly associated with NAFLD in
he deficiency syndrome group and the healthy control group
n the additive model (P  = 0.041, Table 2), the dominant model
P = 0.018, Table 2) and the genotypic distributions (P  = 0.004,
able 2).
Our findings indicated that SCAP rs12636851 SNP exhibited
 positive relationship with NAFLD in the deficiency syndrome
ubjects. Regardless of the syndromes, the frequency of the
s12636851C allele was slightly higher in the NAFLD subjects
han in the healthy controls (χ2 test, P  = 0.038, Table 3). How-
ver, the deficiency syndrome subjects exhibited an association
etween SCAP rs12636851 and NAFLD when the results were
tratified for the deficiency syndrome and excess syndrome.
imilar associations were not seen in the excess syndrome anal-
sis (Table 3). In the deficiency syndrome group, the subjects
ho had the CC or TC genotype had a threefold elevated risk for
AFLD compared with the TT genotype (adjusted OR, 3.107;
5% CI, 1.023–9.433, P  = 0.045; adjusted OR, 2.970; 95% CI,
.121–7.864, P = 0.028). The carriers of the rs12636851C allele
ad an increased prevalence of NAFLD and an OR of 3.017
95% CI, 1.208–7.532; P  = 0.018, when adjusted for age, gen-
er, smoking status, and BMI) compared with the homozygous
f the T allele (Table 3).
t
v
dThe observed rs12636851 distributions in the deficiency and
xcess syndrome groups were shown in Table 4. The ratio of
he subjects with the CC genotype and C allele in the deficiency
yndrome group were larger than that in the excess syndrome
roup after the adjustment for age, gender, smoking status, and
MI (OR, 3.120; 95% CI, 1.334–7.297, P = 0.009; OR, 2.536;
5% CI, 1.250–5.146, P  = 0.010).
iscussion
The results of this study provide preliminary evidence for
he interlinking of SCAP gene polymorphisms to the TCM syn-
romes associated with NAFLD. In the present study, SCAP
s12636851 showed a significant genotype and allelic variation
etween the deficiency syndrome and healthy control subjects
s well as between the deficiency and excess syndrome sub-
ects (when the NAFLD subjects were classified according to
eficiency and excess syndrome). Results suggested that the
eficiency syndrome subjects are genetically susceptible to
AFLD.
Some Chinese herbs have been demonstrated to be successful
n treating hyperlipidemia and fatty liver [20–22]. Thus, TCM
ay be a considerable option for the treatment of NAFLD.
n appropriate and effective TCM treatment is based on a
alid TCM syndrome classification. However, NAFLD is char-
cterized by clinical heterogeneity, and the consensus on the
escription of TCM syndromes is low in literature. Therefore, a
orrespondence between nosology and biomedical background
s necessary to ensure the diagnostic stability of the TCM syn-
romes [23]. Increasing numbers of researchers have explored
he biological and molecular basis of TCM syndromes with
arious methods and achieved remarkable progress [24,25].
In TCM, it is usual to provide different treatments for the same
isease based on the patient’s syndrome classification, which
390 S. Sun et al. / European Journal of Integrative Medicine 5 (2013) 386–392
Table 3
Association between SCAP rs12636851 genotypes and NAFLD.
SNP Healthy control (n = 100) NAFLD (n = 186) Adjusted OR(95% CI) P χ2 P
Xu pattern + Shi pattern
TT 37(37.0) 47(25.3) 1
TC 44(44.0) 90(48.4) 1.711(0.822–3.562) 0.151 4.790 0.091
CC 19(19.0) 49(26.3) 1.700(0.719–4.022) 0.227
TC + CC 63(63.0) 139(74.7) 1.708(0.867–3.362) 0.122 4.385 0.038
Shi pattern
TT 37(37.0) 32(33.7) 1
TC 44(44.0) 43(45.3) 0.972(0.411–2.299) 0.948 0.271 0.845
CC 19(19.0) 20(21.1) 1.061(0.382–2.942) 0.910
TC + CC 63(63.0) 63(66.3) 1.002(0.455–2.207) 0.997 0.234 0.628
Xu pattern
TT 37(37.0) 15(16.5) 1
TC 44(44.0) 47(51.6) 2.970(1.121–7.864) 0.028 11.090 0.004
CC 19(19.0) 29(31.9) 3.107(1.023–9.433) 0.045
TC + CC 63(63.0) 76(83.5) 3.017(1.208–7.532) 0.018 10.122 0.001
Table 4
Association between SCAP rs12636851 genotypes and TCM pattern classification.
SNP Shi pattern (n = 95) Xu pattern (n = 91) Adjusted OR(95% CI) P χ2 P
TT 32(33.7) 15(16.5) 1
TC 43(45.3) 47(51.6) 2.269(1.071–4.804) 0.032 7.897 0.019
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orresponds to the personalized treatment in western medicine.
oreover, genetic information is used for the diagnosis, early
ntervention, and personalized treatment of the disease. The
pparent overlap in the aim of the TCM syndrome classification
nd genetic genotype suggests that genetic polymorphisms may
rovide a scientific evidence for TCM syndrome classification.
n the recent years, several studies made efforts to explain the
CM syndromes from the perspective of genetic polymorphisms
26,27]. In the current study, we classified NAFLD into the
eficiency and excess syndrome. The statistical analysis demon-
trated that SCAP rs12636851 SNP was associated with the
eficiency syndrome. Therefore, this association can provide,
t least in part, a scientific evidence for the validity of the TCM
yndrome classification of NAFLD. In future studies, indepen-
ent and larger populations are needed to replicate and verify
his finding.
A considerable number of studies demonstrated that SCAP
as a central function in lipid metabolism, especially in the
iver [12,28]. Sterol-sensing function is an important func-
ion of SCAP. When cellular cholesterol rises, SCAP senses
he excess cholesterol, and change its conformation in such a
ay that the SCAP/SREBP complex is no longer incorporated
nto the endoplasmic reticulum (ER) transport vesicles; thus
he active fragment cannot reach the nucleus. As a result, the
ynthesis of cholesterol and fatty acids declines [29]. A num-
er of studies reported that mutations on cholesterol-sensing
unction of SCAP influence cholesterol sensitivity and feed-
ack [30,31]. Rs12636851 is located the intron of SCAP. An
dequate understanding on the roles of intronic variants is an
mportant prerequisite to unravel the intricate genetic basis of
s
o
h3.120(1.334–7.297) 0.009
2.536(1.250–5.146) 0.010 7.282 0.007
omplex diseases [32,33]. Common molecular mechanisms for
n intronic SNP to the gene expression are to affect transcrip-
ion, RNA elongation, splicing, or maturation [32]. The SCAP
s12636851 intronic variant in the NAFLD subjects with defi-
iency syndrome maybe impact the splicing of nearby exons
ecause rs12636851 is located between the exons 13 and 14,
esulting in the structural change of SCAP and attenuation of
ts sterol-sensing function. Consistent with this explanation, we
ound that the low-density lipoprotein cholesterol (LDL-c was
lightly higher (P  = 0.039) in the deficiency syndrome group
Table 1). We speculated that due to the attenuation of the sterol-
ensing function of SCAP, SCAP was overproduced, the excess
CAP binding SREBP moved to the Golgi complex, and then
ncreased the synthesis of cholesterol and fatty acids. Choles-
erol and fatty acid biosynthesis occurs mainly in the liver, thus,
he excessive endogenous cholesterol in liver was delivered
o other tissues and cells in LDL through the blood circula-
ion, resulting in the increased LDL-c; meanwhile, excessive
atty acids were accumulated in the liver, resulting in the fatty
iver. This explanation is also reasonable from the TCM view-
oint. The decreased cholesterol sensitivity of SCAP can be
ncluded into the TCM concept of deficiency, which represents
egative, inactive, static, attenuated, inhibited, etc. Thus, such
ccumulating evidence supports the hypothesis that the SCAP
s12636851 polymorphisms in the deficiency syndrome subjects
ffects the cholesterol-sensing function of SCAP, increasing
holesterol and fatty acid synthesis in liver. Therefore, future
tudies are warranted to clarify the mechanism on the effect
f SCAP rs12636851 in the RNA splicing of nearby exons by
eterogeneous nuclear RNA (hnRNA) analysis.
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There are other limitations in our study. Liver biopsy remains
he gold standard for NAFLD diagnosis, but it is associated with
isks and high cost, therefore of limited use in asymptomatic
atients, especially in China. So patients were confirmed with
AFLD by clinical and ultrasonographic (US) diagnosis in our
tudy. In order to limit the potential bias of a false-positive diag-
osis, we selected a strict ultrasonography criterion for NAFLD,
hus some individuals with mild NAFLD might have been mis-
akenly classified into the control group. But because such
 classification generally would decrease the power to detect
ifferences, rather than enhance bias toward a significant dif-
erence, it is unlikely that ultrasonography criterion would have
ontributed to our positive findings.
onclusion
SCAP rs12636851 SNP was positively associated with
AFLD in those deficiency syndrome subjects, but not for those
resenting with the excess syndrome. Thus, this SNP may help
n understanding the genetic basis of NAFLD patients with
eficiency syndrome, and in the development of personalized
edical care. Moreover, this SNP can provide a novel target for
larifying the mechanism of TCM treatment for NAFLD.
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